Introduction: inflammaging and immune system in aging
Humans are metaorganisms: co-evolution between Homo sapiens and the microbiomes
Summary of the main findings on aging and inflammaging referred to the gut microbiome
In addition to the gut microbiome, which role do the other microbiomes play in aging and age-related diseases?
Predominant phyla | Reference | |
---|---|---|
Body site | ||
Mouth | Firmicutes (e.g., Streptococcus); Bacteroidetes (e.g., Prevotella); Proteobacteria (e.g., Haemophilus); Actinobacteria (e.g., Actinomyces); Spirochaetes (e.g., Treponema); Fusobacteria (e.g., Fusobacterium) | |
Nose | Actinobacteria, Bacteroidetes, Firmicutes, Proteobacteria | [157] |
Lung | Proteobacteria, Firmicutes, Bacteroidetes and Actinobacteria | [80] |
Skin | Actinobacteria (Propionibacterium, Corynebacterium) and Firmicutes (Staphylococcus) | |
Gut | Firmicutes (e.g., Lachnospiraceae, Ruminococcaceae), Bacteroidetes (e.g., Bacteroides and/or Prevotella, depending on ethnicity), Actinobacteria (Bifidobacterium, in different abundance according to the host’s age) | |
Vagina | Firmicutes (Lactobacillus) | |
Genito-urinary tract | Actinobacteria (Gardnerella, Corynebacterium) and Firmicutes (Lactobacillus, Streptococcus) |
Oral and nasal microbiome in elderly
Lung microbiome
Skin microbiome and aging
Vaginal microbiome in aging women
Genito-urinary tract microbiome and aging
Body sites | Predominant phyla | Cohort location | Recruited subjects number (age range) | Sequencing stage | α Diversity (taxonomic) | β Diversity (taxonomic) | Aging-related enrichment taxa | Aging-related decreased taxa | Reference | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Young | Elderly | Longevity | Shannon index | Richness | variation among individuals | ||||||||
Gut | Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria | Sardinia (Italy) | 19 (21–33) | 23 (68–88) | 19 (99–107) | Illumina Hiseq and Miseq | Shotgun metagenomic sequencing and 16S rRNA V3V4 | ≈ | ≈ | ↑ | Methanobrevibacter smithii, Bifidobacterium adolescentis | Faecalibacterium prausnitzii, Eubacterium rectale | [145] |
Firmicutes, Bacteroidetes | Bologna (Italy) | 20 (25–40) | 43 (59–78) | 21 (99–104) | Phylogentic microarry and qPCR | 16S rRNA | ↓ | ↓ | Anaerotruncus, Oscillospira, Christensenellaceae, Eggerthella | Faecalibacterium, Roseburia, Coprococcus | [146] | ||
Skin | Actinobacteria | Sardinia (Italy) | 19 (21–33) | 23 (68–88) | 19 (99–107) | Illumina Hiseq and Miseq | Shotgun metagenomic sequencing and 16S rRNA V3V4 | Site-dependent alterations | ↑ | Staphylococcus, Streptococcus | Propionibacterium | [99] | |
Actinobacteria | Shangai (China), urban and rural | 24 (25–35) | 22 (50–60) | 454 Pyrosequencing | 16S rRNA | ≈ | ↓ | [97] | |||||
Actinobacteria | Japan | 18 (23–37) | 19 (60–76) | 454 Pyrosequencing | 16S rRNA | ↑ | ↑ | Corynebacterium, Acinetobacter | Propionibacterium, Staphylococcus | [98] | |||
Mouth | Firmicutes (EN), Bacteroidetes (HC) | Osaka, Japan | 16 (79–94) | 15 (68–101) | Pyrosequencing | 16S | ↓ (EN) | Actinomyces, Streptococcus, Bacilli, Selenomonas, Veillonella, Haemophilus (increased in EN) | Prevotella, Leptotrichia, Campylobacter, and Fusobacterium (decreased in EN) | [71] | |||
Cambridge, USA/São Paulo, Brazil | periodontis: young 152 (28.5 ± 4.7), middle 833 (35–64); periodontally healthy: young 119 (29.24 ± 6.2), middle 112 (35–64) | periodontitis 99 (69.6 ± 4.2); periodontally healthy 15 (67.8 ± 9.8) | Checkerboard DNA–DNA hybridization | Actinomyces (increase d in elderly with periodontal) | P. gingivalis and T. forsythia (increased in younger with periodontal) | [73] | |||||||
Firmicutes | Danbury, CT, USA | 33 (70–82) | 32 (70–82) | illumina Miseq | 16S | ↑(healthy aging) | Streptococcus, Veillonella, and Rothia (NHA) | Neisseria, Haemophilus, Fusobacterium, and Capnocytophaga are enriched in healthy aging. | [72] | ||||
Actinobacteria (in AMD) | Ontario, Canada | 5 (<59–89) | 13 (60>89) | Illumina NextSeq500 | 16S | Propionibacteriales, Rothia, Staphylococcus, and Cornyebacteriaceae (increased in AMD) | Fusobacterium and Bacilli (higher in controls) | [78] | |||||
Nose | Ontario, Canada | 5 (<59–89) | 13 (60>89) | Illumina NextSeq500 | 16S | Actinomycetaceae, Gemella, Proteobacteria, Actinomyces, Veillonella, Burkholderiales (significantly higher in AMD) | Clostridia (increased in the control group) | [78] | |||||
Lung (sputum) | Firmicutes, Proteobacteria, Bacteroidetes, Actinobacteria | Singapore | 24 (22–39) | 24 (60–71) | MiSeq Illumina | 16S | Not significant different | Not significant different | Not significant different | Firmicutes | Proteobacteria (Haemophilus, Lautropia) | [85] | |
Bladder (urine) | Proteobacteria, Firmicutes | Zhejiang, China | 50 (50.06 ± 7.51) | 50 (71.86 ± 6.70) | MiSeq Illumina | 16S V3V4 | ↓ (Not significant) | ↓ (Not significant) | Peptococcus | Lactobacillus, Bifidobacteria | [134] | ||
Firmicutes | UK | 23 (20–29) | 14 (50–59) | Eurofins Genomics | 16S | Not significant different | Not significant different | Mobiluncus | lactobacillus | [148] | |||
Firmicutes, Proteobacteria | Bristol, UK | 13 (20–49) | 20 (50–70+) | 454 Pyrosequencing | 16SV1V3 | Not significant different | Not significant different | Jonquetella, Parvimonas, Proteiniphilum, and Saccharofermentans. | [152] |